FDA Approves Bizengri for Rare NRG1 Fusion-Positive Cholangiocarcinoma
The FDA authorized Bizengri to treat adults with advanced cholangiocarcinoma with NRG1 gene fusion, marking the seventh approval under its National Priority Voucher pilot…
Health & Public Health covers major developments in healthcare, medicine, medical research, public health, food safety, health policy, insurance, drug safety, and safety issues affecting readers in the United States and around the world. This section focuses on clear, factual reporting from credible sources, including government health agencies, medical research institutions, public health organizations, and trusted news outlets. Coverage may include FDA updates, NIH research, disease prevention, healthcare costs, medication safety, public health alerts, hospital systems, and policy decisions that affect patients and communities.